TNDM — Tandem Diabetes Care Share Price
Last trade - 00:00- $1.20bn
- $1.11bn
- $940.20m
- 70
- 40
- 44
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.57 | ||
| Price to Tang. Book | 4.59 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.28 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.93% | ||
| Return on Equity | -33.3% | ||
| Operating Margin | -10.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 498.83 | 702.8 | 801.22 | 747.72 | 940.2 | 999.58 | 1,108.27 | 21.01% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
Directors
- Kim Blickenstaff CHM (68)
- John Sheridan PRE (65)
- Leigh Vosseller CFO (48)
- Susan Morrison EVP (41)
- David Berger EVP (51)
- Elizabeth Gasser EVP (45)
- Brian Hansen EVP (53)
- Rick Carpenter CTO
- Jordan Pinsker VPR
- Dick Allen LED (76)
- Peyton Howell IND (54)
- Kathleen McGroddy-Goetz IND (57)
- Rebecca Robertson IND (60)
- Douglas Roeder IND (50)
- Rajwant Sodhi IND (47)
- Christopher Twomey IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 7th, 2008
- Public Since
- November 13th, 2013
- No. of Shareholders
- 41
- No. of Employees
- 2,650
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 66,563,301
- Address
- 12400 High Bluff Drive, SAN DIEGO, 92130
- Web
- https://www.tandemdiabetes.com/
- Phone
- +1 8583666900
- Auditors
- Ernst & Young LLP
Latest News for TNDM
Upcoming Events for TNDM
Q1 2025 Tandem Diabetes Care Inc Earnings Release
Q1 2025 Tandem Diabetes Care Inc Earnings Call
Tandem Diabetes Care Inc Annual Shareholders Meeting
Tandem Diabetes Care Inc Annual Shareholders Meeting
Q2 2025 Tandem Diabetes Care Inc Earnings Release
Similar to TNDM
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
As of Today at 23:35 UTC, shares in Tandem Diabetes Care are trading at $18.06. This share price information is delayed by 15 minutes.
Shares in Tandem Diabetes Care last closed at $18.06 and the price had moved by -49.21% over the past 365 days. In terms of relative price strength the Tandem Diabetes Care share price has underperformed the S&P500 Index by -53.12% over the past year.
The overall consensus recommendation for Tandem Diabetes Care is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreTandem Diabetes Care does not currently pay a dividend.
Tandem Diabetes Care does not currently pay a dividend.
Tandem Diabetes Care does not currently pay a dividend.
To buy shares in Tandem Diabetes Care you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $18.06, shares in Tandem Diabetes Care had a market capitalisation of $1.20bn.
Here are the trading details for Tandem Diabetes Care:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TNDM
Based on an overall assessment of its quality, value and momentum Tandem Diabetes Care is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Tandem Diabetes Care is $39.24. That is 117.28% above the last closing price of $18.06.
Analysts covering Tandem Diabetes Care currently have a consensus Earnings Per Share (EPS) forecast of -$1.26 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tandem Diabetes Care. Over the past six months, its share price has underperformed the S&P500 Index by -39.28%.
As of the last closing price of $18.06, shares in Tandem Diabetes Care were trading -46.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Tandem Diabetes Care PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $18.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Tandem Diabetes Care's management team is headed by:
- Kim Blickenstaff - CHM
- John Sheridan - PRE
- Leigh Vosseller - CFO
- Susan Morrison - EVP
- David Berger - EVP
- Elizabeth Gasser - EVP
- Brian Hansen - EVP
- Rick Carpenter - CTO
- Jordan Pinsker - VPR
- Dick Allen - LED
- Peyton Howell - IND
- Kathleen McGroddy-Goetz - IND
- Rebecca Robertson - IND
- Douglas Roeder - IND
- Rajwant Sodhi - IND
- Christopher Twomey - IND